The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

por Kim, Sunkyu, Tiedt, Ralph, Loo, Alice, Horn, Thomas, Delach, Scott, Kovats, Steven, Haas, Kristy, Engstler, Barbara Schacher, Cao, Alexander, Pinzon-Ortiz, Maria, Mulford, Iain, Acker, Michael G., Chopra, Rajiv, Brain, Christopher, di Tomaso, Emmanuelle, Sellers, William R., Caponigro, Giordano
Publicado 2018

Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

por Kim, Sunkyu, Tiedt, Ralph, Loo, Alice, Horn, Thomas, Delach, Scott, Kovats, Steven, Haas, Kristy, Engstler, Barbara Schacher, Cao, Alexander, Pinzon-Ortiz, Maria, Mulford, Iain, Acker, Michael G., Chopra, Rajiv, Brain, Christopher, Tomaso, Emmanuelle di, Sellers, William R., Caponigro, Giordano
Publicado 2020

Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition

por Fassl, Anne, Brain, Christopher, Abu-Remaileh, Monther, Stukan, Iga, Butter, Deborah, Stepien, Piotr, Feit, Avery S., Bergholz, Johann, Michowski, Wojciech, Otto, Tobias, Sheng, Qing, Loo, Alice, Michael, Walter, Tiedt, Ralph, DeAngelis, Carmine, Schiff, Rachel, Jiang, Baishan, Jovanovic, Bojana, Nowak, Karolina, Ericsson, Maria, Cameron, Michael, Gray, Nathanael, Dillon, Deborah, Zhao, Jean J., Sabatini, David M., Jeselsohn, Rinath, Brown, Myles, Polyak, Kornelia, Sicinski, Piotr
Publicado 2020